MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
432.60
-0.19
-0.04%
After Hours: 434.98 +2.38 +0.55% 19:57 11/10 EST
OPEN
428.43
PREV CLOSE
432.79
HIGH
443.30
LOW
424.02
VOLUME
459.04K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
353.54
MARKET CAP
10.05B
P/E (TTM)
-72.5571
1D
5D
1M
3M
1Y
5Y
1D
Is Madrigal Pharmaceuticals (MDGL) Cheap Following Rezdiffra Data And A Swing To Net Income?
Simply Wall St · 10h ago
These healthcare stocks have tumbled in 2026, yet Quant ratings stay positive
Seeking Alpha · 13h ago
Madrigal’s Balanced Outlook Supports Hold as Competition Risks Rise; Price Target Unchanged at $479
TipRanks · 20h ago
Weekly Report: what happened at MDGL last week (1102-1106)?
Weekly Report · 1d ago
Madrigal Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Madrigal Pharmaceuticals (MDGL)
Barchart · 1d ago
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Barchart · 2d ago
What Does Madrigal Pharmaceuticals (MDGL) Whistleblower Probe Mean For Investors?
Simply Wall St · 2d ago
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
PR Newswire · 4d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.